Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Pain

Angiotensin II type 2 receptor (ATGR2)

In vitro and mouse studies suggest agonizing ATGR2 could help prevent pain. In a murine cell-based screen of about 8,000 siRNAs, Atgr2 was identified as a receptor that mediates the analgesic effect of the mycobacterial toxin mycolactone. In mice, Atgr2 knockout prevented mycolactone-induced analgesia. Next steps include developing an ATGR2 ligand to treat pain.
Mitsubishi Tanabe Pharma Corp. has the ATGR2 agonist MP-157 in Phase I testing to treat hypertension.
At least two other companies have ATGR2 agonists in preclinical development for cardiovascular and pulmonary indications.

SciBX 7(28); doi:10.1038/scibx.2014.833
Published online July 24, 2014

Patent application filed; available for licensing

Marion, E. et al. Cell; published online June 19, 2014;
doi:10.1016/j.cell.2014.04.040
Contact: Priscille Brodin, Institute Pasteur Korea, Gyeonggi-do, South Korea
e-mail:

priscille.brodin@inserm.fr
Contact: Laurent Marsollier, Institut National de la Santé et de la Recherche Médicale (INSERM) Avenir, Angers, France
e-mail:

laurent.marsollier@inserm.fr